The cream nobody told you about

There’s a prescription that stops vaginal dryness, makes sex stop hurting, and cuts recurrent urinary infections by about ninety percent. It barely enters your bloodstream. It’s been around for decades. It’s free in BC. And most women hear about it, if they hear about it at all, from a podcast in their fifties.

It’s low-dose vaginal estrogen: a cream, an insert, or a ring.

What it’s for

When estrogen falls, the tissue of the vagina, vulva and lower bladder thins and dries. The medical name is genitourinary syndrome of menopause, and it affects somewhere between a quarter and four-fifths of women after menopause, rising with the years¹. Dryness, burning, itching, pain with sex, urgency, and bladder infections that keep coming back. Unlike hot flashes, it doesn’t pass. It gets worse.

In a survey of 1,858 American women with these symptoms, half had never used any treatment for it¹.

Why it’s different from hormone therapy

Estrogen through the skin or by mouth goes everywhere; that’s the point, and it’s why it needs thought. Vaginal estrogen goes where you put it. Blood levels on the low-dose products stay in the normal post-menopause range, around 5 to 10 picograms per millilitre with the ring¹. Because so little gets through, no progesterone is needed to protect the uterus¹. It doesn’t treat hot flashes or protect bone; it isn’t trying to.

That’s also why women who take systemic hormone therapy sometimes still need it: the dose that fixes your sleep may not reach the tissue¹.

The bladder part

This is the finding that should be on a billboard. In a trial of 93 women with recurrent urinary infections, an estrogen cream cut infections from 5.9 a year to 0.5². The urology guidelines that Canadian urologists follow now say clinicians should recommend vaginal estrogen to peri- and postmenopausal women with recurrent infections³. If you’ve had three UTIs this year and nobody mentioned it, this is the sentence to bring to your next visit.

Safety, including after breast cancer

The warning label that scared everyone off systemic hormone therapy in 2002 was printed on the vaginal products too, though the risks it described came from pills at higher doses. In November 2025 the US regulator moved to take that warning off low-dose vaginal estrogen; the Menopause Society called it “a safe and effective therapy for a condition that affects most menopausal women”⁴.

After estrogen-sensitive breast cancer, the American college of obstetricians says vaginal estrogen can be used when non-hormonal moisturizers and lubricants haven’t worked, in discussion with your oncologist⁵.

How it’s used, and what it costs

Cream: nightly for two weeks, then two or three times a week. Insert: the same pattern. Ring: put in and changed every three months. Improvement takes a few weeks; stopping means the symptoms return.

Since March 1, 2026, Premarin vaginal cream and the Imvexxy insert are fully covered by BC PharmaCare for anyone with MSP⁶. Your family doctor can prescribe it; so can a nurse practitioner. If you’d rather start with something over the counter, moisturizers and lubricants help many women, and our vaginal dryness check walks through which to try first.

---

Sources

1. The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement. Menopause 2020;27(9):976–992. “Genitourinary syndrome of menopause affects approximately 27% to 84% of postmenopausal women”; “In a survey of 1,858 US postmenopausal women with genitourinary symptoms, 50% had never used any therapy for this problem”; ring serum estradiol “5 pg/mL to 10 pg/mL”; “When low-dose vaginal estrogen … is administered, a progestogen is not indicated”; dosing regimens; additional vaginal estrogen may be added for women on systemic therapy. https://www.isswsh.org/images/content/2020-NAMS-GSM-Paper.pdf
2. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753–756. 93 women; infections per patient-year 0.5 (estriol) vs 5.9 (placebo). Summary: https://clinician.nejm.org/topical-estrogens-prevent-uti-postmenopausal-women-JW199309240000004
3. American Urological Association, Canadian Urological Association, SUFU. Recurrent uncomplicated urinary tract infections in women: guideline (2019, amended 2022), Statement 20: “clinicians should recommend vaginal estrogen therapy to reduce the risk of future UTIs if there is no contraindication.” https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti
4. The Menopause Society. Comments on the FDA announcement on hormone therapy. November 10, 2025. “We agree with the FDA’s decision to remove the boxed warning on low-dose vaginal estrogen therapies”; “a safe and effective therapy for a condition that affects most menopausal women.” https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy
5. American College of Obstetricians and Gynecologists. Committee Opinion 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. 2016. “Vaginal estrogen should be reserved for those patients who are unresponsive to nonhormonal remedies.” https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/03/the-use-of-vaginal-estrogen-in-women-with-a-history-of-estrogen-dependent-breast-cancer
6. Government of British Columbia. Plan NP menopausal hormone therapy. Premarin vaginal cream and Imvexxy 4 mcg and 10 mcg inserts listed as full benefit from March 1, 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/plans/national-pharmacare-plan-np/plan-np-menopausal-hormone-therapy

This article is general information, not medical advice. The medical professional who sees you in person may reach a different assessment, and their judgement takes precedence.